Avian Flu news from FierceBiotech
News
Limerick raises $15M; Icahn offered $15B for Biogen; Neogen expands R&D
> Limerick BioPharma has ginned $11 million in venture funds and borrowed $4 million more to advance its work on the bioavailability of drugs. Arch Venture Partners, Sevin Rosen Funds and Altitude Read more...
ALSO NOTED: Researchers testing stem cell therapy for CHF; Boehringer unveils new research center; and much more...
> Fifty-six of the nation's most creative biomedical scientists are being given the opportunity to tackle their most ambitious, risky research plans, as they become the newest class of Howard Read more...
ALSO NOTED: FDA, Medicare team up on drug surveillance; Early stage prostate vaccine shows promise; and much more...
> FDA is teaming up with the Center for Medicare and Medicaid Services on data-mining. FDA will be able to probe CMS's patient databases, actively looking for potential safety problems. Next, the Read more...
GSK bird flu vaccine wins race for European OK
After investing about $2 billion in development efforts, GlaxoSmithKline has won European approval for the first bird flu vaccine that can be used either in advance of or in the early days of a human Read more...
ALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...
> Ambrilia Biopharma reported positive 24-week Phase III top-line results for prolonged-release formulation of Octreotide. Read more...
Intercell snaps up Iomai in $189M deal
The little Maryland-based vaccine developer Iomai, which has posted some impressive data on a new therapy for Read more...
ALSO NOTED: AMA joins DTC advertising fray; U.K. toughening up on pharma promos; and much more...
> We all expected Democrats to rake DTC ads over the coals during yesterday's hearing before the House Energy and Commerce Committee's oversight arm. What we didn't expect was for the American Read more...
ALSO NOTED: Dyax to close R&D facility;Nastech sells shares; and much more...
> Dyax says it plans to close its research facility in Belgium as it focuses on commercializing DX-88 to treat hereditary angioedema. Read more...
ALSO NOTED: Isotechnika reports psoriasis success; Romark enrolls hep C patients; and much more...
> Isotechnika's ISA247 has demonstrated significant efficacy against psoriasis. Report > Romark Laboratories Read more...
Feds ok Iomai Phase II adjuvant patch study
Health and Human Services is giving Iomai the green light to do a mid-stage dose ranging study of its adjuvant patch for bird flu vaccine. HHS provided a $128 million contract backing Iomai's effort Read more...
Get more Avian Flu coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets